Login
Companies $UNCY
$3.70 +$0.00 (0.0%) After hours
Unicycive Therapeutics, Inc. logo

Unicycive Therapeutics, Inc.

unicycive.com

What Do They Do?

Develops drug candidates for kidney disease, including a phosphate binder for dialysis patients and a treatment for acute kidney injury.

Who Are Their Customers?

Pharmaceutical partners license OLC rights for Greater China and select Asian markets, then handle regulatory approval and commercialization or distribution in those territories.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −16% (Loss)
vs −$6M in Q3 FY2025

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support